Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, was featured in a recent Proactive interview. Mark Dybul, CEO of Renovaro, joined host Steve Darling to talk about the company and its achievements and potential. Specifically, the two talked about the company’s recent signing of a definitive agreement to merge with GEDiCube, a United-Kingdom-based medical artificial intelligence (“AI”) company renowned for its contributions to the early detection and remission of cancer, as well as expedited drug discovery. During the interview, Dybul discussed the plan to rebrand GEDiCube as Renovaro.AI and then have the two entities work together to accelerate diagnosis processes, improve the efficacy of treatments, pioneer new therapies, and broaden the availability of vital technologies for cancer and other diseases.
Dybul also mentioned that although Renovaro is focused on pancreatic cancer research, the company is planning to extend its focus to include other solid tumors that are typically associated with a short life expectancy. Part of that expansion will include making those tumors as part of the first human phase I/IIa studies anticipated to commence by mid-2024. Dybul also talked about the potential of GEDiCube’s AI technology to support the company’s focus of upcoming human trials on those cancers that are most amenable to treatment. In addition, the company expects the technology to supplement the database of crucial markers for early diagnosis and tracking disease progression, consequently furthering the development of novel iterations of Renovaro’s treatment methodologies and the discovery of new therapeutic options.
To view the interview, visit https://ibn.fm/YMdv3
To view the full press release, visit https://ibn.fm/4TKf0
About Renovaro BioSciences Inc.
Renovaro BioSciences has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information about the company, visit www.RenovaroBio.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]